Effect of zerumbone on scopolamine-induced memory impairment and anxiety-like behaviours in rats.
Alzheimer's disease
Anxiety
Dementia
Hyperactivity
Learning and memory deficit
Scopolamine
Zerumbone
Journal
Alzheimer's & dementia (New York, N. Y.)
ISSN: 2352-8737
Titre abrégé: Alzheimers Dement (N Y)
Pays: United States
ID NLM: 101650118
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
We investigated the effects of zerumbone (1 and 10 mg/kg) against hyperactivity, anxiety and memory impairment in scopolamine-induced dementia in Sprague-Dawley rats. Open field tests, elevated plus maze and Morris water maze were performed to assess general locomotor activity, anxiety-like behaviours and learning and memory processes respectively in rats pretreated with scopolamine. Scopolamine-treated rats showed high total activity, stereotype, and total distance travelled in the open field arena, reduced number of entries to open arms, decreased the percentage of time spent in open arms and higher escape latency time in the Morris water maze test. Interestingly, single administration of zerumbone (1 and 10 mg/kg) reversed the hyperactivity, anxiety-like behaviours, and learning impairment effects of scopolamine in the three experimental model studied respectively. Our findings demonstrated that the scopolamine-induced impairment of learning and memory was reversed by the administration of zerumbone. As a conclusion, our findings presented the positive effects of zerumbone on dementia-like behaviours in the animal model used and could possibly contribute for future research to manage hyperactivity, anxiety, and learning disabilities.
Identifiants
pubmed: 31687471
doi: 10.1016/j.trci.2019.09.009
pii: S2352-8737(19)30070-8
pmc: PMC6819871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
637-643Informations de copyright
© 2019 The Authors.
Références
Sci Adv. 2016 Jun 03;2(6):e1501672
pubmed: 27386561
Carcinogenesis. 2002 May;23(5):795-802
pubmed: 12016152
Pharm Biol. 2017 Dec;55(1):958-965
pubmed: 28166686
Nat Rev Neurol. 2011 Mar;7(3):137-52
pubmed: 21304480
Oncogene. 2005 Oct 20;24(46):6957-69
pubmed: 16007145
J Vis Exp. 2015 Feb 06;(96):e52434
pubmed: 25742564
Behav Neurosci. 2015 Aug;129(4):540-8
pubmed: 26214219
Alzheimers Res Ther. 2014 Aug 18;6(4):48
pubmed: 25484926
Nutr Cancer. 2003;45(2):218-25
pubmed: 12881017
Mol Neurobiol. 2016 Nov;53(9):6557-6567
pubmed: 26768430
Biomed Res Int. 2014;2014:927804
pubmed: 25133184
Int J Cancer. 2004 Jul 1;110(4):481-90
pubmed: 15122579
Alzheimers Dement. 2014 Mar;10(2):e47-92
pubmed: 24818261
Life Sci. 2014 Jul 30;109(2):73-86
pubmed: 25066372